Methotrexate-resistant Variants of Human Dihydrofolate Reductase with Substitutions of Leucine 22

@article{Lewis1995MethotrexateresistantVO,
  title={Methotrexate-resistant Variants of Human Dihydrofolate Reductase with Substitutions of Leucine 22},
  author={William S Lewis and Vivian Cody and Nikolai Galitsky and Joseph R. Luft and Walter A. Pangborn and Srinivas K. Chunduru and Harold Trent Spencer and James R. Appleman and Raymond L. Blakley},
  journal={The Journal of Biological Chemistry},
  year={1995},
  volume={270},
  pages={5057 - 5064}
}
Although substitution of tyrosine, phenylalanine, tryptophan, or arginine for leucine 22 in human dihydrofolate reductase greatly slows hydride transfer, there is little loss in overall activity (kcat) at pH 7.65 (except for the arginine 22 variant), but Km for dihydrofolate and NADPH are increased significantly. The greatest effect, decreased binding of methotrexate to the enzyme-NADPH complex by 740- to 28,000-fold due to a large increase in the rate of methotrexate dissociation, makes these… Expand
Active site-directed double mutants of dihydrofolate reductase.
TLDR
Comparison of in vitro measured properties with those of single-residue variants indicates that double mutants are indeed significantly superior, and this was verified for one of the double mutants that provided high-level methotrexate resistance following retrovirus-mediated gene transfer in NIH3T3 cells. Expand
Multiple Conformers in Active Site of Human Dihydrofolate Reductase F31R/Q35E Double Mutant Suggest Structural Basis for Methotrexate Resistance*
TLDR
It is demonstrated that the important decrease of methotrexate affinity in variant F31R/Q35E is a result of synergistic effects of the combined substitutions, and the multiple conformers of Arg-31 further suggest that the amino acid substitutions may decrease the isomerization step required for tight binding of metotrexate. Expand
Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase.
TLDR
The MTX-resistant hDHFRs can protect eukaryotic cells from MTX toxicity by transfecting the most resistant mutants into DHFR-knock-out CHO cells, and offer potential for myeloprotection during administration of MTX in cancer treatment. Expand
Identification of Amino Acids Required for the Functional Up-regulation of Human Dihydrofolate Reductase Protein in Response to Antifolate Treatment*
TLDR
Evidence is provided that the adaptive up-regulation of DHFR by methotrexate contributes to the decreased sensitivity to this drug, and a new model is proposed whereby DHFR exists in two conformations, one bound to DHFR mRNA and the other bound to NADPH. Expand
In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: Potential for clinical application
TLDR
Introduction of some of these mutants into mammalian cells by retroviral transfer provides substantial protection from toxic effects of the inhibitors, and has promise for the myeloprotection of patients receiving therapy with methotrexate or trimetrexate. Expand
Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH.
TLDR
The unexpected results from this comparison of the mouse and human DHFR complexes bound with the same ligand and cofactor illustrate the importance of detailed study of several species of enzyme, even when there is a high sequence homology between them. Expand
Structural characteristics of antifolate dihydrofolate reductase enzyme interactions
The ubiquitous enzyme dihydrofolate reductase (DHFR) is responsible for the reduction of 5,6-dihydrofolate to 5,6,7,8-tetrahydrofolate in an NADPH-dependent manner. It is also a key pharmacologicalExpand
Species-Specific Differences in Translational Regulation of Dihydrofolate Reductase
TLDR
It is shown that unlike what was observed in human cells, dihydrofolate reductase (DHFR) levels do not increase in hamster cells after methotrexate exposure, and evidence is presented to suggest that the translational up-regulation of dihydofolate reducesase by metotrexate in tumor cells is an adaptive mechanism that decreases sensitivity to this drug. Expand
The solution structure of the complex of Lactobacillus casei dihydrofolate reductase with methotrexate.
TLDR
The three-dimensional solution structure of the complex of Lactobacillus casei dihydrofolate reductase formed with the anticancer drug methotrexate is determined using 2531 distance, 361 dihedral angle and 48 hydrogen bond restraints obtained from analysis of multidimensional NMR spectra. Expand
Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants.
TLDR
Retroviral transduction of antifolate-resistant variants of human dihydrofolate reductase (hDHFR) into cells can increase their resistance to the cytotoxic effects of these drugs, but the resistance differences depending on hDHFR expression levels differ. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe31 substitutions.
TLDR
Presteady-state measurements have enabled a complete catalytic scheme to be constructed for the glycine variant that predicts observed steady-state behavior and best fulfills criteria for gene therapy: low Km for H2folate, high kcat, and good stability. Expand
Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis.
TLDR
Five variants of human dihydrofolate reductase are constructed in which smaller residues are substituted for phenylalanine 34, a residue participating in the binding of substrate and methotrexate by interaction with their pteridine rings, and it is shown that, like the wild-type enzyme, the variants have a branched reaction pathway, but the distribution of flux between alternate pathways is dependent on the concentration of dihydofolate. Expand
Role of aspartate 27 in the binding of methotrexate to dihydrofolate reductase from Escherichia coli.
Dihydrofolate reductase from wild-type Escherichia coli (WT-ECDHFR) and from a mutant enzyme in which aspartate 27 is replaced by asparagine have been compared with respect to the binding of theExpand
Kinetic investigation of the functional role of phenylalanine-31 of recombinant human dihydrofolate reductase.
TLDR
The results indicate that there is no quantitative correlation between dihydrofolate binding and the rate of hydride transfer for this enzyme, and a mechanism proceeding almost entirely by only one of the two pathways used by wt enzyme. Expand
Effect of codon 22 mutations on substrate and inhibitor binding for human dihydrofolate reductase.
TLDR
Results suggest that codon 22 may be a “hot spot” which readily mutates to impart a MTX-resistant phenotype to its host cell. Expand
Role of the conserved active site residue tryptophan-24 of human dihydrofolate reductase as revealed by mutagenesis.
TLDR
The question of why even the very conservative replacement of this tryptophan by phenylalanine does not seem to occur naturally is addressed and the most critical changes resulting from the amino acid substitution appear to be a 50% decrease in stability and a decrease in efficiency. Expand
Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase.
TLDR
The kinetics of inhibitor binding to highly purified recombinant human dihydrofolate reductase (rHDHFR) have been examined and it follows that the significance ofMTX polyglutamate formation relates to other roles such as increasing the cytotoxicity of MTX by prolonging intracellular retention of the drug. Expand
Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation.
TLDR
Purified altered enzyme displays significantly lower binding affinity for the antifolates MTX, trimetrexate, edatrexate, and trimethoprim with respective Ki values 165, 76, 30, and 28-fold higher than values obtained for enzyme isolated from parental tumor (wild-type enzyme). Expand
Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts.
TLDR
Studies with various folic acid analogs suggest that modifications involving the para-aminobenzoyl moiety of the inhibitor molecules are associated with the most dramatic differential binding between the altered and wild type dihydrofolate reductases. Expand
Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance.
TLDR
It was observed that codon 22 variants were generally more resistant to MTX, but codon 31 variants retained substantially more catalytic activity at a given level of MTX resistance, which has important implications for the function of different DHFR variants as mediators of drug resistance. Expand
...
1
2
3
4
...